Yannick Allanore

Q: What Schools Are Affiliated With Yannick Allanore

Yannick Allanore is affiliated with the following schools: Université Paris Cité, University of Verona, Stanford University, Paris Diderot University

Yannick Allanore's AcademicInfluence.com Rankings

Yannick Allanore

Chemistry

#3154

World Rank

#4146

Historical Rank

Polymer Chemistry

#86

World Rank

#89

Historical Rank

Organic Chemistry

#499

World Rank

#577

Historical Rank

chemistry Degrees

Yannick Allanore

Engineering

#4637

World Rank

#5847

Historical Rank

Materials Science

#226

World Rank

#229

Historical Rank

Applied Physics

#1175

World Rank

#1203

Historical Rank

engineering Degrees

Download Badge

Chemistry
Engineering

Yannick Allanore's Degrees

PhD Materials Science Université Paris Cité
Masters Chemistry Université Paris Cité
Bachelors Chemistry Université Paris Cité

Why Is Yannick Allanore Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Yannick Allanore's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. (2013) (2731)
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative (2013) (1713)
Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database (2010) (1000)
Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. (2005) (738)
Update of EULAR recommendations for the treatment of systemic sclerosis (2015) (712)
Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. (2009) (619)
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial (2016) (429)
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases (2004) (419)
Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. (2009) (394)
Systemic sclerosis (2021) (356)
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group (2014) (355)
Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group (2010) (344)
Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. (2012) (338)
Mapping and predicting mortality from systemic sclerosis (2017) (328)
Prevalence of Pulmonary Hypertension in Systemic Sclerosis in European Caucasians and Metaanalysis of 5 Studies (2010) (267)
Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis (2017) (264)
Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database (2012) (251)
Primary myocardial involvement in systemic sclerosis. (2006) (242)
MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease (2018) (240)
High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. (2008) (228)
Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. (2003) (228)
Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis (2009) (214)
Genome-Wide Scan Identifies TNIP1, PSORS1C1, and RHOB as Novel Risk Loci for Systemic Sclerosis (2011) (210)
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. (2020) (205)
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate) (2017) (204)
Cardiac involvement in systemic sclerosis assessed by tissue-doppler echocardiography during routine care: A controlled study of 100 consecutive patients. (2008) (204)
Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. (2009) (192)
The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. (2009) (187)
Radiological hand involvement in systemic sclerosis (2006) (186)
Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study (2008) (179)
International consensus criteria for the diagnosis of Raynaud's phenomenon. (2014) (177)
Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study (2012) (175)
Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis (2013) (169)
Characteristics of Joint Involvement and Relationships with Systemic Inflammation in Systemic Sclerosis: Results from the EULAR Scleroderma Trial and Research Group (EUSTAR) Database (2010) (169)
COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study (2021) (158)
High risk of clinical cardiovascular events in rheumatoid arthritis: Levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis. (2010) (157)
STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. (2009) (156)
The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy (2009) (150)
Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease (2011) (148)
Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials (2013) (144)
The MUC5B Variant Is Associated with Idiopathic Pulmonary Fibrosis but Not with Systemic Sclerosis Interstitial Lung Disease in the European Caucasian Population (2013) (142)
Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease (2017) (140)
Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study (2016) (136)
Systemic sclerosis-associated Sjögren's syndrome and relationship to the limited cutaneous subtype: results of a prospective study of sicca syndrome in 133 consecutive patients. (2006) (135)
Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator‐Initiated, Multicenter, Double‐Blind, Randomized, Placebo‐Controlled Trial (2020) (132)
Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study (2019) (130)
Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. (2008) (130)
Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis (2017) (123)
Digital ulcers predict a worse disease course in patients with systemic sclerosis (2015) (122)
Association of the TNFAIP3 rs5029939 variant with systemic sclerosis in the European Caucasian population (2010) (122)
Heart involvement in systemic sclerosis: evolving concept and diagnostic methodologies. (2010) (122)
N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. (2003) (119)
Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study (2016) (119)
Effects of corticosteroids and immunosuppressors on idiopathic inflammatory myopathy related myocarditis evaluated by magnetic resonance imaging (2006) (117)
Primary myocardial involvement in systemic sclerosis: evidence for a microvascular origin. (2010) (115)
"To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity. (2012) (113)
BANK1 is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects with IRF5 and STAT4. (2009) (113)
The PTPN22 620W allele confers susceptibility to systemic sclerosis: findings of a large case-control study of European Caucasians and a meta-analysis. (2008) (110)
Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study (2013) (108)
The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index (2016) (106)
Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres (2011) (105)
Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials (2013) (104)
Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases (2013) (102)
High ischemia-modified albumin concentration reflects oxidative stress but not myocardial involvement in systemic sclerosis. (2004) (101)
Levels of circulating endothelial progenitor cells in systemic sclerosis. (2007) (99)
Prevalence of Barrett's esophagus in systemic sclerosis. (2005) (98)
Body mass index influences the response to infliximab in ankylosing spondylitis (2012) (97)
Hand vascular involvement assessed by magnetic resonance angiography in systemic sclerosis. (2007) (96)
Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature (2019) (95)
Circulating endothelial progenitor cells in systemic sclerosis: association with disease severity (2008) (95)
EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells (2008) (94)
Vitamin D Deficiency and Insufficiency in 2 Independent Cohorts of Patients with Systemic Sclerosis (2009) (93)
Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs (2008) (93)
Systemic sclerosis: state of the art on clinical practice guidelines (2018) (91)
Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database (2020) (90)
Evaluation of the effect of nifedipine upon myocardial perfusion and contractility using cardiac magnetic resonance imaging and tissue Doppler echocardiography in systemic sclerosis (2005) (88)
Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis. (2012) (87)
Ultrasonographic hand features in systemic sclerosis and correlates with clinical, biologic, and radiographic findings (2012) (87)
Infectious sacroiliitis: a retrospective, multicentre study of 39 adults (2012) (87)
Cardiac arrhythmias and conduction defects in systemic sclerosis. (2014) (86)
Predictive factors of hand radiographic lesions in systemic sclerosis: a prospective study (2010) (86)
High prevalence of right ventricular systolic dysfunction in early systemic sclerosis. (2004) (85)
Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease. (2011) (85)
NLRP1 influences the systemic sclerosis phenotype: a new clue for the contribution of innate immunity in systemic sclerosis-related fibrosing alveolitis pathogenesis (2010) (85)
A descriptive and prognostic study of systemic sclerosis-associated myopathies (2008) (84)
A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study (2014) (84)
Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for Screening (2017) (82)
Articular involvement in systemic sclerosis. (2012) (82)
Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab (2006) (81)
Raynaud phenomenon and digital ulcers in systemic sclerosis (2020) (80)
Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model (2018) (80)
Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials (2007) (79)
Acute and sustained effects of dihydropyridine-type calcium channel antagonists on oxidative stress in systemic sclerosis. (2004) (79)
Methotrexate and rheumatoid arthritis associated interstitial lung disease (2020) (79)
Prevalence, Correlates and Outcomes of Gastric Antral Vascular Ectasia in Systemic Sclerosis: A EUSTAR Case-control Study (2014) (79)
Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. (2006) (78)
GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways (2019) (77)
Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab. (2004) (77)
Bosentan increases myocardial perfusion and function in systemic sclerosis: a magnetic resonance imaging and Tissue-Doppler echography study. (2006) (77)
Impaired quality of life in systemic sclerosis and patient perception of the disease: A large international survey. (2016) (77)
Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group (2018) (76)
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. (2021) (75)
Performance of Candidate Serum Biomarkers for Systemic Sclerosis–Associated Interstitial Lung Disease (2019) (75)
Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. (2011) (75)
Increased risk of osteoporosis and fracture in women with systemic sclerosis: A comparative study with rheumatoid arthritis (2012) (72)
Targeting synovial neoangiogenesis in rheumatoid arthritis. (2017) (70)
The Nrf2-Antioxidant Response Element Signaling Pathway Controls Fibrosis and Autoimmunity in Scleroderma (2018) (70)
Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis (2015) (69)
Transethnic meta-analysis identifies GSDMA and PRDM1 as susceptibility genes to systemic sclerosis (2017) (68)
Angiogenesis in systemic sclerosis: impaired expression of vascular endothelial growth factor receptor 1 in endothelial progenitor-derived cells under hypoxic conditions. (2008) (68)
Correlations between angiogenic factors and capillaroscopic patterns in systemic sclerosis (2013) (68)
Prostaglandin transporter mutations cause pachydermoperiostosis with myelofibrosis (2012) (68)
Systemic sclerosis: an update in 2008. (2008) (68)
Sequential nailfold videocapillaroscopy examinations have responsiveness to detect organ progression in systemic sclerosis. (2017) (67)
Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin. (2008) (67)
Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis (2014) (66)
Associated Autoimmune Diseases in Systemic Sclerosis Define a Subset of Patients with Milder Disease: Results from 2 Large Cohorts of European Caucasian Patients (2010) (66)
Myopathies related to systemic sclerosis: a case–control study of associated clinical and immunological features (2010) (65)
Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab (2020) (65)
Phenotype-Haplotype Correlation of IRF5 in Systemic Sclerosis: Role of 2 Haplotypes in Disease Severity (2010) (64)
Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France. (2017) (64)
Prognostic factors for lung function in systemic sclerosis: prospective study of 105 cases (2009) (63)
Systemic sclerosis: Recent insights. (2015) (62)
Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. (2014) (62)
Lack of Specificity of the 6-Minute Walk Test as an Outcome Measure for Patients with Systemic Sclerosis (2009) (62)
Decreased prevalence of atopy in rheumatoid arthritis (1998) (61)
Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations. (2011) (61)
Sustained response to infliximab in 2 patients with refractory relapsing polychondritis. (2003) (61)
Brief report: candidate gene study in systemic sclerosis identifies a rare and functional variant of the TNFAIP3 locus as a risk factor for polyautoimmunity. (2012) (61)
Myocardial contractility is early affected in systemic sclerosis: a tissue Doppler echocardiography study. (2005) (61)
Anti-RNA Polymerase III Antibody Prevalence and Associated Clinical Manifestations in a Large Series of French Patients with Systemic Sclerosis: A Cross-sectional Study (2010) (61)
Evaluation of depression and anxiety in patients with systemic sclerosis. (2005) (61)
Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort (2019) (60)
Systemic sclerosis at the crossroad of polyautoimmunity. (2013) (60)
Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise (2012) (60)
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis (2016) (60)
Functional disability and its predictors in systemic sclerosis: a study from the DeSScipher project within the EUSTAR group (2018) (60)
Coagulation factor XIII: a multifunctional transglutaminase with clinical potential in a range of conditions (2015) (60)
Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis (2015) (60)
Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis (2019) (59)
Association of the CD226 Ser(307) variant with systemic sclerosis: evidence of a contribution of costimulation pathways in systemic sclerosis pathogenesis. (2011) (59)
Anticyclic Citrullinated Peptide Antibodies in Rheumatoid and Nonrheumatoid Rheumatic Disorders: Experience with 1162 Patients (2014) (59)
Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis (2018) (58)
High DNA Oxidative Damage in Systemic Sclerosis (2010) (58)
Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) Definition (2017) (58)
A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. (2017) (58)
Increased plasma soluble CD40 ligand concentrations in systemic sclerosis and association with pulmonary arterial hypertension and digital ulcers (2004) (58)
New therapeutic strategies in the management of systemic sclerosis (2007) (58)
Association between an endoglin gene polymorphism and systemic sclerosis-related pulmonary arterial hypertension. (2006) (57)
Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis (2016) (57)
Hand and wrist involvement in systemic sclerosis: US features. (2013) (57)
Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database (2015) (56)
Outcomes of Barrett's oesophagus related to systemic sclerosis: a 3-year EULAR Scleroderma Trials and Research prospective follow-up study. (2011) (56)
Is there a role for TNFα antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique. (2011) (55)
Trained immunity modulates inflammation-induced fibrosis (2019) (54)
Independent replication establishes the CD247 gene as a genetic systemic sclerosis susceptibility factor (2011) (53)
Inflammation and Disease Activity are Associated with High Circulating Cardiac Markers in Rheumatoid Arthritis Independently of Traditional Cardiovascular Risk Factors (2014) (53)
Regulatory T Cells in Systemic Sclerosis (2018) (53)
IgG reactivity with a 100-kDa tissue and endothelial cell antigen identified as topoisomerase 1 distinguishes between limited and diffuse systemic sclerosis patients. (2004) (53)
Nifedipine decreases sVCAM-1 concentrations and oxidative stress in systemic sclerosis but does not affect the concentrations of vascular endothelial growth factor or its soluble receptor 1 (2004) (53)
Angiogenic biomarkers predict the occurrence of digital ulcers in systemic sclerosis (2011) (53)
Evidence of the contribution of the X chromosome to systemic sclerosis susceptibility: association with the functional IRAK1 196Phe/532Ser haplotype. (2011) (52)
Systemic sclerosis and cardiac dysfunction: evolving concepts and diagnostic methodologies (2008) (52)
The interferon regulatory factor 5 gene confers susceptibility to rheumatoid arthritis and influences its erosive phenotype (2010) (52)
Alveolar concentration of nitric oxide predicts pulmonary function deterioration in scleroderma (2011) (52)
Reduced incidence and prevalence of atopy in rheumatoid arthritis. Results of a case-control study. (2000) (52)
Cardiovascular disease in rheumatoid arthritis: single-center hospital-based cohort study in France. (2007) (52)
Cardiac Biomarkers in Systemic Sclerosis: Contribution of High‐Sensitivity Cardiac Troponin in Addition to N‐Terminal Pro‐Brain Natriuretic Peptide (2015) (52)
C8orf13-BLK is a genetic risk locus for systemic sclerosis and has additive effects with BANK1: results from a large french cohort and meta-analysis. (2011) (51)
Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension (2017) (50)
Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management (2020) (50)
Limited Value of Temporal Artery Ultrasonography Examinations for Diagnosis of Giant Cell Arteritis: Analysis of 77 Subjects (2010) (50)
Effects of rituximab in connective tissue disorders related interstitial lung disease. (2016) (49)
Erectile dysfunction is frequent in systemic sclerosis and associated with severe disease: a study of the EULAR Scleroderma Trial and Research group (2012) (49)
Prevalence of antiphospholipid antibodies in systemic sclerosis and association with primitive pulmonary arterial hypertension and endothelial injury. (2005) (49)
Association of a KCNA5 gene polymorphism with systemic sclerosis-associated pulmonary arterial hypertension in the European Caucasian population. (2010) (49)
Evaluation of interleukin 13 polymorphisms in systemic sclerosis (2006) (49)
Serum protein oxidation in patients with rheumatoid arthritis and effects of infliximab therapy. (2006) (48)
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial (2020) (48)
N-terminal pro-brain natriuretic peptide in systemic sclerosis: a new cornerstone of cardiovascular assessment? (2008) (48)
N-terminal pro brain natriuretic peptide: the new cornerstone of cardiovascular assessment in systemic sclerosis. (2009) (48)
THE ROLE OF CHEST CT IN DECIPHERING INTERSTITIAL LUNG INVOLVEMENT: SYSTEMIC SCLEROSIS VERSUS COVID-19. (2021) (47)
A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis. (2011) (47)
Review: Defining a Unified Vascular Phenotype in Systemic Sclerosis (2018) (46)
OX40L blockade protects against inflammation-driven fibrosis (2016) (46)
Genetic basis for systemic sclerosis. (2007) (46)
Genetic background of systemic sclerosis: autoimmune genes take centre stage. (2010) (45)
IL13RA2 gene polymorphisms are associated with systemic sclerosis. (2006) (45)
Endothelial progenitor cells and rheumatic disorders. (2008) (45)
Trabecular Bone Score in Female Patients with Systemic Sclerosis: Comparison with Rheumatoid Arthritis and Influence of Glucocorticoid Exposure (2015) (44)
Autoantibodies against Endothelin 1 Type A Receptor Are Strong Predictors of Digital Ulcers in Systemic Sclerosis (2015) (44)
Anti-endothelial cell antibodies from patients with limited cutaneous systemic sclerosis bind to centromeric protein B (CENP-B). (2006) (43)
Rituximab therapy in rheumatoid arthritis in daily practice. (2008) (43)
Points to consider for skin ulcers in systemic sclerosis (2017) (43)
Comparison of pain, pain burden, coping strategies, and attitudes between patients with systemic sclerosis and patients with rheumatoid arthritis: a cross-sectional study. (2013) (43)
Rheumatic and Musculoskeletal Features of Whipple Disease: A Report of 29 Cases (2013) (43)
Expert consensus for performing right heart catheterisation for suspected pulmonary arterial hypertension in systemic sclerosis: a Delphi consensus study with cluster analysis (2013) (42)
Enhanced late-outgrowth circulating endothelial progenitor cell levels in rheumatoid arthritis and correlation with disease activity (2010) (42)
Efficacy and Safety of Tocilizumab for the Treatment of Systemic Sclerosis: Results from a Phase 3 Randomized Controlled Trial (2019) (42)
Lack of association between the protein tyrosine phosphatase non-receptor 22 (PTPN22)*620W allele and systemic sclerosis in the French Caucasian population (2006) (41)
Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: A 12-year longitudinal multi-center study. (2018) (41)
Regulatory T Cell Dysfunction in Idiopathic, Heritable and Connective Tissue-Associated Pulmonary Arterial Hypertension. (2016) (41)
Decreased expression of neuropilin-1 as a novel key factor contributing to peripheral microvasculopathy and defective angiogenesis in systemic sclerosis (2015) (41)
A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis (2020) (41)
Arthritis in systemic sclerosis: systematic review of the literature and suggestions for the performance of future clinical trials in systemic sclerosis arthritis. (2012) (39)
Immunogenetics of systemic sclerosis. (2011) (39)
High redox thioredoxin but low thioredoxin reductase activities in the serum of patients with rheumatoid arthritis. (2006) (39)
Systemic sclerosis trial design moving forward (2016) (39)
Low levels of nitric oxide (NO) in systemic sclerosis: inducible NO synthase production is decreased in cultured peripheral blood monocyte/macrophage cells. (2001) (39)
Combined effect of genetic background and gender in a mouse model of bleomycin-induced skin fibrosis (2015) (39)
Prostaglandin I2 analogues enhance already exuberant Th17 cell responses in systemic sclerosis (2012) (39)
MDCT imaging of calcinosis in systemic sclerosis. (2013) (39)
Correlation of serum collagen I carboxyterminal telopeptide concentrations with cutaneous and pulmonary involvement in systemic sclerosis. (2003) (38)
Identification of NF-κB and PLCL2 as new susceptibility genes and highlights on a potential role of IRF8 through interferon signature modulation in systemic sclerosis (2015) (38)
IgG4-related skin disease successfully treated by thalidomide: a report of 2 cases with emphasis on pathological aspects. (2013) (37)
Late Nailfold Videocapillaroscopy Pattern Associated With Hand Calcinosis and Acro‐Osteolysis in Systemic Sclerosis (2016) (37)
Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database. (2019) (37)
Independent Replication and Metaanalysis of Association Studies Establish TNFSF4 as a Susceptibility Gene Preferentially Associated with the Subset of Anticentromere-positive Patients with Systemic Sclerosis (2012) (37)
Cardiovascular magnetic resonance in systemic sclerosis: "Pearls and pitfalls". (2017) (37)
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis (2016) (36)
Prevalence and predictors of small intestinal bacterial overgrowth in systemic sclerosis patients with gastrointestinal symptoms. (2014) (36)
Osteoarticular involvement in a series of 100 patients with sarcoidosis referred to rheumatology departments. (2008) (36)
Association between rheumatoid arthritis and primary biliary cirrhosis. (2007) (36)
The genetics of systemic sclerosis: an update. (2011) (36)
RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis. (2017) (35)
Safety of rituximab in rheumatoid arthritis: a long-term prospective single-center study of gammaglobulin concentrations and infections. (2012) (35)
Clinical and biochemical heterogeneity associated with fumarase deficiency (2011) (34)
Critical role of the adhesion receptor DNAX accessory molecule-1 (DNAM-1) in the development of inflammation-driven dermal fibrosis in a mouse model of systemic sclerosis (2012) (34)
Lack of association between three vascular endothelial growth factor gene polymorphisms and systemic sclerosis: results from a multicenter EUSTAR study of European Caucasian patients (2006) (34)
Associations between a scleroderma-specific gastrointestinal instrument and objective tests of upper gastrointestinal involvements in systemic sclerosis. (2013) (34)
A relationship between TGF-beta 1 or IL-6 plasma levels and clinical features of spondyloarthropathies. (1997) (34)
Autoantibody induction in patients with refractory spondyloarthropathy treated with infliximab and methotrexate. (2005) (34)
Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus. (2019) (33)
ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis—a EUSTAR analysis (2020) (33)
Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis (2019) (33)
Nifedipine protects against overproduction of superoxide anion by monocytes from patients with systemic sclerosis (2004) (33)
Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards. (2015) (33)
Scleroderma: From pathogenesis to comprehensive management (2011) (33)
Treatment of systemic sclerosis–associated interstitial lung disease: Lessons from clinical trials (2020) (32)
Male microchimerism and HLA compatibility in French women with sclerodema: a different profile in limited and diffuse subset. (2009) (32)
Evidence for caveolin-1 as a new susceptibility gene regulating tissue fibrosis in systemic sclerosis (2012) (32)
T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis (2018) (32)
Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features (2019) (31)
A regulatory variant in CCR6 is associated with susceptibility to antitopoisomerase-positive systemic sclerosis. (2013) (31)
Clinical characteristics and predictors of gangrene in patients with systemic sclerosis and digital ulcers in the Digital Ulcer Outcome Registry: a prospective, observational cohort (2016) (31)
Imaging Findings Suggestive of Axial Spondyloarthritis in Diffuse Idiopathic Skeletal Hyperostosis (2018) (31)
Arterial stiffness predicts severe progression in systemic sclerosis: the ERAMS study (2007) (31)
Vitamin D levels and potential impact in systemic sclerosis. (2011) (31)
Systemic sclerosis in 2014: Advances in cohort enrichment shape future of trial design (2015) (30)
Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design. (2010) (30)
Subluxing arthropathy: an unusual manifestation of the antisynthetase syndrome (2008) (30)
Insights into the pathogenesis of systemic sclerosis based on the gene expression profile of progenitor-derived endothelial cells. (2011) (29)
An international SUrvey on non-iNvaSive tecHniques to assess the mIcrocirculation in patients with RayNaud’s phEnomenon (SUNSHINE survey) (2017) (29)
Outcome measures for heart involvement in systemic sclerosis. (2008) (29)
Association of hypoxia‐inducible factor 1A (HIF1A) gene polymorphisms with systemic sclerosis in a French European Caucasian population (2009) (29)
Familial Autoimmunity in Systemic Sclerosis — Results of a French-based Case-Control Family Study (2012) (28)
Myocardial dysfunction in rheumatoid arthritis: a controlled tissue-Doppler echocardiography study. (2007) (28)
Use of biologics and other novel therapies for the treatment of systemic sclerosis (2017) (28)
Patient phenotypes in fibromyalgia comorbid with systemic sclerosis or rheumatoid arthritis: influence of diagnostic and screening tests. Screening with the FiRST questionnaire, diagnosis with the ACR 1990 and revised ACR 2010 criteria. (2017) (28)
Safety and effectiveness of abatacept in systemic sclerosis: The EUSTAR experience. (2020) (28)
Circulating lung biomarkers in idiopathic lung fibrosis and interstitial lung diseases associated with connective tissue diseases: Where do we stand? (2020) (28)
Development and validation of French version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. (2011) (28)
Targeting Costimulatory Pathways in Systemic Sclerosis (2018) (27)
Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population (2015) (27)
EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research (2011) (26)
Skin Telangiectasia and the Identification of a Subset of Systemic Sclerosis Patients With Severe Vascular Disease (2015) (26)
Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study (2019) (26)
The need for a holistic approach for SSc-ILD – achievements and ambiguity in a devastating disease (2020) (26)
Lack of association of eNOS (G894T) and p22phox NADPH oxidase subunit (C242T) polymorphisms with systemic sclerosis in a cohort of French Caucasian patients. (2004) (26)
Association Study of ITGAM, ITGAX, and CD58 Autoimmune Risk Loci in Systemic Sclerosis: Results from 2 Large European Caucasian Cohorts (2011) (25)
Increased prevalence of ocular glaucomatous abnormalities in systemic sclerosis (2004) (25)
Epistatic Interaction between BANK1 and BLK in Rheumatoid Arthritis: Results from a Large Trans-Ethnic Meta-Analysis (2013) (25)
Effects of successive switches to different biosimilars infliximab on immunogenicity in chronic inflammatory diseases in daily clinical practice. (2020) (25)
A candidate gene study reveals association between a variant of the Peroxisome Proliferator-Activated Receptor Gamma (PPAR-γ) gene and systemic sclerosis (2015) (25)
IL-1 receptor blockade skews inflammation towards Th2 in a mouse model of systemic sclerosis (2019) (25)
Systemic sclerosis: recent insight in clinical management. (2020) (25)
An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years (2021) (24)
Muscle involvement in systemic sclerosis: points to consider in clinical trials (2017) (24)
Identification of secreted phosphoprotein 1 gene as a new rheumatoid arthritis susceptibility gene. (2015) (23)
Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study (2018) (23)
Enhanced expression of ephrins and thrombospondins in the dermis of patients with early diffuse systemic sclerosis: potential contribution to perturbed angiogenesis and fibrosis. (2011) (22)
Soluble CD163 as a Potential Biomarker in Systemic Sclerosis (2018) (22)
Combination of Echocardiographic and Pulmonary Function Test Measures Improves Sensitivity for Diagnosis of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: Analysis of 2 Cohorts (2013) (22)
The clinical phenotype of Systemic Sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort. (2021) (22)
Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis (2020) (22)
Systemic sclerosis pathogenesis: contribution of recent advances in genetics (2020) (22)
Mortality profile of patients with rheumatoid arthritis in France and its change in 10 years. (2017) (22)
Experimental models of dermal fibrosis and systemic sclerosis. (2013) (21)
Efficacy of rituximab in the treatment of pulmonary rheumatoid nodules: findings in 10 patients from the French AutoImmunity and Rituximab/Rheumatoid Arthritis registry (AIR/PR registry) (2012) (21)
Limited cutaneous systemic sclerosis: the unfairly neglected subset (2016) (21)
Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS) (2021) (21)
One year in review 2020: systemic sclerosis. (2020) (21)
Double-blind, Randomized, 8-week Placebo-controlled followed by a 16-week open label extension study, with the LPA1 receptor antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis (2018) (21)
Development of a five-year mortality model in systemic sclerosis patients by different analytical approaches. (2010) (21)
A right ventricular diastolic impairment is common in systemic sclerosis and is associated with other target-organ damage. (2016) (21)
Worldwide Expert Agreement on Updated Recommendations for the Treatment of Systemic Sclerosis (2019) (20)
Updating the genetics of systemic sclerosis (2010) (20)
Novel LRP5 gene mutation in a patient with osteoporosis-pseudoglioma syndrome. (2010) (20)
Decreased expression of the endothelial cell-derived factor EGFL7 in systemic sclerosis: potential contribution to impaired angiogenesis and vasculogenesis (2013) (20)
Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. (2020) (20)
Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis (2018) (20)
French recommendations for the management of systemic sclerosis (2021) (19)
Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes (2021) (19)
Latitude gradient influences the age of onset of rheumatoid arthritis: a worldwide survey (2017) (19)
Increased Ed-B fibronectin plasma levels in spondyloarthropathies: comparison with rheumatoid arthritis patients and a healthy population. (1999) (19)
Early trajectories of skin thickening are associated with severity and mortality in systemic sclerosis (2020) (18)
European multicentre study validates enhanced liver fibrosis test as biomarker of fibrosis in systemic sclerosis (2018) (18)
Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study. (2020) (18)
Factors linked to disease activity in a French cohort of patients with spondyloarthropathy. (1998) (17)
Estrogens counteract the profibrotic effects of TGF-β and their inhibition exacerbates experimental dermal fibrosis. (2020) (17)
18F-fluorodeoxyglucose positron-emission tomography/CT and lung involvement in systemic sclerosis (2018) (17)
From VEDOSS to established systemic sclerosis diagnosis according to ACR/EULAR 2013 classification criteria: a French-Italian capillaroscopic survey. (2018) (17)
Treatment of systemic sclerosis. (2006) (16)
N-terminal pro-brain natriuretic peptide is a strong predictor of mortality in systemic sclerosis. (2016) (16)
Outcome of Patients with Systemic Sclerosis in the Intensive Care Unit (2015) (16)
Transient hyperthyroidism in a patient with rheumatoid arthritis treated by etanercept. (2001) (16)
Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher study (2019) (16)
What have multicentre registries across the world taught us about the disease features of systemic sclerosis? (2017) (16)
Polymorphic markers of the fibrillin-1 gene and systemic sclerosis in European Caucasian patients. (2008) (16)
Flare of calcinosis despite rituximab therapy. (2014) (16)
Treatment of systemic sclerosis: is there any hope for the future? (2016) (16)
Comparing HLA Shared Epitopes in French Caucasian Patients with Scleroderma (2012) (16)
Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study (2019) (16)
OP0054 Safety and Efficacy of Subcutaneous Tocilizumab in Adults with Systemic Sclerosis: Week 48 Data from the Fasscinate Trial (2015) (16)
Variations of neuronal nitric oxide synthase in systemic sclerosis skin. (2006) (16)
Role of Stromelysin 2 (Matrix Metalloproteinase 10) as a Novel Mediator of Vascular Remodeling Underlying Pulmonary Hypertension Associated With Systemic Sclerosis (2017) (16)
Association study of B-cell marker gene polymorphisms in European Caucasian patients with systemic sclerosis. (2011) (16)
Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study (2018) (15)
Coccidioidomycosis of the spine in an immunocompetent patient. (2010) (15)
The Nuclear Receptor Constitutive Androstane Receptor/NR1I3 Enhances the Profibrotic Effects of Transforming Growth Factor β and Contributes to the Development of Experimental Dermal Fibrosis (2014) (15)
Improving risk-stratification of rheumatoid arthritis patients for interstitial lung disease (2020) (15)
TGFβ receptor gene variants in systemic sclerosis-related pulmonary arterial hypertension: results from a multicentre EUSTAR study of European Caucasian patients (2012) (15)
Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis. (2015) (14)
The arachidonate 5-lipoxygenase activating protein gene polymorphism is associated with the risk of scleroderma-related interstitial lung disease: a multicentre European Scleroderma Trials and Research group (EUSTAR) study (2017) (14)
Targeting CD226/DNAX accessory molecule-1 (DNAM-1) in collagen-induced arthritis mouse models (2015) (14)
Common measure of quality of life for people with systemic sclerosis across seven European countries: a cross-sectional study (2018) (14)
Targeted immunotherapies in systemic sclerosis. (2014) (14)
Takayasu Arteritis and Spondyloarthritis: Coincidence or Association? A Study of 14 Cases (2017) (14)
Small, medium but not large arteries are involved in digital ulcers associated with systemic sclerosis. (2016) (14)
Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis (2020) (14)
Systemic sclerosis and gastric MALT lymphoma. (2006) (14)
Interstitial pneumonia with autoimmune features: a new classification still on the move (2018) (14)
Diagnostic Tools (2018) (14)
[Pathophysiology of systemic sclerosis]. (2016) (13)
Gender differences in early systemic sclerosis patients: a report from the EULAR scleroderma trials and research group (EUSTAR) database. (2018) (13)
Differences associated with age at onset in early systemic sclerosis patients: a report from the EULAR Scleroderma Trials and Research Group (EUSTAR) database (2018) (13)
Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database (2020) (13)
Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database (2020) (13)
Genomic Risk Score impact on susceptibility to systemic sclerosis (2020) (13)
Comparative efficacy and safety of treatments for secondary Raynaud's phenomenon: a systematic review and network meta-analysis of randomised trials (2019) (13)
Management of a patient with sarcoid calcaneitis and dactylitis. (2001) (12)
Points to consider for designing trials in systemic sclerosis patients with arthritic involvement (2017) (12)
Association of Metalloproteinase Gene Polymorphisms with Systemic Sclerosis in the European Caucasian Population (2010) (12)
Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis (2018) (12)
Intravenous versus oral cyclophosphamide for lung and/or skin fibrosis in systemic sclerosis: an indirect comparison from EUSTAR and randomised controlled trials. (2020) (12)
Angiotensin-Converting Enzyme Gene Does Not Contribute to Genetic Susceptibility to Systemic Sclerosis in European Caucasians (2009) (12)
Implication of the deacetylase sirtuin-1 on synovial angiogenesis and persistence of experimental arthritis (2020) (12)
Incomplete thymic involution in systemic sclerosis and rheumatoid arthritis. (2013) (12)
Association between Rheumatoid Arthritis and Pulmonary Hypertension: Data from the French Pulmonary Hypertension Registry (2018) (12)
OP0245 PRESERVATION OF LUNG FUNCTION OBSERVED IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL OF TOCILIZUMAB FOR THE TREATMENT OF EARLY SSC (2019) (12)
Nailfold capillary abnormalities in erectile dysfunction of systemic sclerosis: a EUSTAR group analysis. (2014) (12)
Hemodynamic changes after acute fluid loading in patients with systemic sclerosis without pulmonary hypertension (2018) (11)
Risk factors of impaired humoral response to COVID-19 vaccination in rituximab-treated patients (2021) (11)
Association between RANK, RANKL and OPG polymorphisms with ACPA and erosions in rheumatoid arthritis: results from a meta-analysis involving three French cohorts (2016) (11)
Dermal tissue and cellular expression of fibrillin-1 in diffuse cutaneous systemic sclerosis. (2010) (11)
The Role of Chest CT in Deciphering Interstitial Lung Involvement: Systemic Sclerosis Versus COVID-19 (2021) (11)
Early phase clinical and biological markers associated with subclinical atherosclerosis measured at 7 years of evolution in an early inflammatory arthritis cohort. (2016) (11)
Sinus aspergilloma in rheumatoid arthritis before or during tumor necrosis factor-alpha antagonist therapy (2009) (11)
Usefulness of routine electrocardiography for heart disease screening in patients with spondyloarthropathy or rheumatoid arthritis. (2010) (11)
SAR100842, an Antagonist of Lysophaphatidic Acid Receptor 1, As a Potential Treatment for Patients with Systemic Sclerosis: Results from a Phase 2a Study. (2014) (11)
Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis (2017) (10)
Nintedanib in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score (2021) (10)
Association Study of Serotonin Transporter Gene (SLC6A4) in Systemic Sclerosis in European Caucasian Populations (2010) (10)
The limited cutaneous form of systemic sclerosis is associated with urinary incontinence: an international multicentre study (2017) (10)
Association study of 3 rheumatoid arthritis risk loci in systemic sclerosis in European Caucasian population. (2011) (10)
IgG from patients with systemic sclerosis bind to DNA antitopoisomerase 1 in normal human fibroblasts extracts (2008) (10)
Natural variability in the disease course of SSc-ILD: implications for treatment (2021) (9)
Randomised controlled trials in systemic sclerosis: patient selection and endpoints for next generation trials (2020) (9)
Bosentan-Induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome (2010) (9)
A Practical Approach to the Management of Digital Ulcers in Patients With Systemic Sclerosis: A Narrative Review. (2021) (9)
Candidate Gene Study in Systemic Sclerosis Identifies a Rare and Functional Variant of the TNFAIP 3 Locus as a Risk Factor for Polyautoimmunity (2012) (9)
Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual (2019) (8)
Is There a Place for Chimeric Antigen Receptor–T Cells in the Treatment of Chronic Autoimmune Rheumatic Diseases? (2021) (8)
Polymorphisms in the interleukin 4, interleukin 13 and corresponding receptor genes are not associated with Systemic Sclerosis and do not influence gene expression (2010) (8)
Interleukin 6 Blockade in Spondyloarthritis (2012) (8)
OP0059 Phenotypes Determined by Cluster Analysis and their Survival in the Prospective Eustar Cohort of Patients with Systemic Sclerosis (2015) (8)
Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey (2019) (8)
Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials (2021) (8)
Circulating collagen neo-epitopes and their role in the prediction of fibrosis in patients with systemic sclerosis: a multicentre cohort study (2021) (7)
Disseminated extrapulmonary tuberculosis revealed by humeral osteomyelitis with chronic unremarkable pain. (2005) (7)
TNF receptor-associated periodic syndrome (TRAPS): a new cause of joint destruction? (2009) (7)
Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort. (2019) (7)
Sacral inflammatory pseudotumor revealed by paraneoplastic syndrome (2004) (7)
Pseudotumoral calcinosis in systemic sclerosis: Data from systematic literature review and case series from two referral centres. (2020) (7)
Semaphorins: From Angiogenesis to Inflammation in Rheumatoid Arthritis (2021) (7)
A very rare cause of acro-osteolysis: Hajdu-Cheney syndrome. (2015) (7)
Performance of skin ultrasound to measure skin involvement in different animal models of systemic sclerosis. (2013) (7)
Points to consider when doing a trial primarily involving the heart (2017) (7)
Multiple spontaneous visceral hematomas revealing polyarteritis nodosa. (2004) (7)
Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies (2021) (7)
Severe Refractory Rheumatoid Arthritis Successfully Treated with Combination Rituximab and Anti-Tumor Necrosis Factor-α-Blocking Agents (2009) (7)
Cardiovascular mortality in patients with inflammatory rheumatic disorders. (2007) (7)
Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition (2021) (7)
Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes (2020) (7)
OP0035 Preliminary analysis of nailfold capillaroscopy in the very early diagnosis of systemic sclerosis (VEDOSS): the capi-vedoss experience (2017) (7)
Prevalence and Disease‐Specific Risk Factors for Lower Urinary Tract Symptoms in Systemic Sclerosis: An International Multicenter Study (2018) (7)
Brachial Plexopathy associated with Systemic Sclerosis (2002) (6)
Improvement with time of vascular outcomes in systemic sclerosis: a systematic review and meta-analysis study. (2021) (6)
FRI0129 Switch between reference etanercept (ETN) and gp2015, an etanercept biosimilar, did not impact efficacy and safety in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase 3 equira study (2018) (6)
All-cause Mortality Associated with TNF-α Inhibitors in Rheumatoid Arthritis: A Meta-Analysis of Randomized Controlled Trials. (2015) (6)
Scleroderma renal crisis: Case reports and update on critical issues. (2020) (6)
OP0065 THE VERY EARLY DIAGNOSIS OF SYSTEMIC SCLEROSIS (VEDOSS) PROJECT: PREDICTORS TO DEVELOP DEFINITE DISEASE FROM AN INTERNATIONAL MULTICENTRE STUDY (2019) (6)
SAT0163 Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory rheumatic diseases in daily clinical practice: the experience of cochin hospital, paris, france (2017) (6)
OP0183 EFFICACY AND SAFETY OF RIOCIGUAT IN PATIENTS WITH EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS AND INTERSTITIAL LUNG DISEASE (SSC-ILD): RESULTS FROM THE PHASE IIB RISE-SSC STUDY (2019) (6)
OP0266 Lysophophatidic Acid Receptor 1 Antagonist SAR100842 as a Potential Treatment for Patients with Systemic Sclerosis: Results from a Phase 2A Study (2015) (6)
OP0226 Expert consensus for performing right heart catheterization in suspicion of pulmonary arterial hypertension associated with systemic sclerosis: A delphi consensus study with cluster analysis from the eposs group (2013) (6)
Efficacy of rituximab in patients with rheumatoid arthritis refractory or with contra-indication to anti-tumor necrosis factor-alpha drugs in daily practice: an open label observational study. (2007) (6)
Usefulness of Multidetector Computed Tomography to Assess Calcinosis in Systemic Sclerosis (2008) (6)
Evaluation of Nifedipine efficacy upon myocardial perfusion and contractility using cardiac Magnetic Resonance Imaging and Tissue Doppler echocardiography in Systemic Sclerosis (2005) (5)
SAT0013 Candidate gene study in systemic sclerosis identifies a rare and functional variant of TNFAIP3 locus as a risk factor for individual polyautoimmunity (2013) (5)
OP0249 LONG-TERM EXTENSION RESULTS OF RISE-SSC, A RANDOMIZED TRIAL OF RIOCIGUAT IN PATIENTS WITH EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC) (2020) (5)
Ethnic influence on the phenotype of French patients with systemic sclerosis. (2020) (5)
[Management of digital ulcers from systemic scleroderma]. (2008) (5)
Risk of liver fibrosis induced by methotrexate and other rheumatoid arthritis medications according to the Fibrosis-4 Index. (2021) (5)
AB0007 Shared genetic predisposition in rheumatoid arthritis–interstitial lung disease and familial pulmonary fibrosis (2017) (5)
[Interactions between fibrillin-1 and tgf-beta: consequences and human pathology]. (2009) (5)
POS0054 THE IMPACT AND OUTCOME OF COVID-19 ON SYSTEMIC SCLEROSIS PATIENTS FROM THE EUROPEAN SCLERODERMA TRIAL AND RESEARCH GROUP (EUSTAR) (2021) (5)
SS.1.1 Decrease activity of DNA demethylase in SSC fibroblast and microvascular endothelial cells: a possible mechanism for persistent SSC phenotype (2012) (5)
Patient perception of disease burden in diffuse cutaneous systemic sclerosis (2019) (5)
French translation and linguistic validation of the Raynaud's condition score. (2019) (5)
Impact of EUSTAR standardized training on accuracy of modified Rodnan skin score in patients with systemic sclerosis (2018) (5)
Lung function preservation in a phase 3 trial of tocilizumab (TCZ) in systemic sclerosis (SSc) (2019) (5)
Systemic sclerosis and primary biliary cholangitis: An overlapping entity? (2018) (5)
Efficacy and Safety of Riociguat in Patients with Early Diffuse Cutaneous Systemic Sclerosis and Interstitial Lung Disease (SSc-ILD): Results from the Phase IIb RISE-SSc Study (2019) (5)
Six-week antibiotic therapy after one-stage replacement arthroplasty for hip and knee periprosthetic joint infection. (2020) (5)
IL-2-related regulatory CD4 T-cell deficiency leads to the development of lung fibrosis and vascular remodeling. (2022) (5)
Predominant primitive right ventricular involvement in systemic sclerosis. (2007) (5)
Successful treatment of severe interstitial pneumonia by removal of circulating autoantibodies: a case series (2021) (4)
[Heart involvement in systemic sclerosis]. (2006) (4)
OP0239 PROGRESSIVE LUNG FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE IN THE EUSTAR DATABASE (2019) (4)
Systemic Sclerosis Classification Criteria: Developing methods for multi-criteria decision analysis with 1000Minds (2014) (4)
Dyspnoea and cough in patients with systemic sclerosis–associated interstitial lung disease in the SENSCIS trial (2022) (4)
Preservation of Lung Function Observed in a Phase 3 Randomized Controlled Trial of Tocilizumab for the Treatment of Early Systemic Sclerosis (2019) (4)
OP0250 EFFICACY AND SAFETY OF ROMILKIMAB IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC): RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 24-WEEK, PROOF OF CONCEPT STUDY (2020) (4)
A leptomeningeal metastasis revealed by sciatica. (1999) (4)
S.7.1 Ultrasonographic hand features in systemic sclerosis and correlates with clinical, biological and radiographic findings (2012) (4)
Digital ulcers: should debridement be a standard of care in systemic sclerosis? (2020) (4)
Comparison of the clinical phenotype of systemic sclerosis patients in Iran and France in two university centers (2018) (4)
Disease Activity Score in 28 Joints Using GGT Permits a Dual Evaluation of Joint Activity and Cardiovascular Risk (2020) (4)
Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment (2022) (4)
rheumatism collaborative initiative rheumatology / European league against sclerosis : an American college of 2013 classification criteria for systemic (2013) (4)
FRI0303 THE EFFECTS OF RIOCIGUAT ON RAYNAUD’S PHENOMENON AND DIGITAL ULCERS IN PATIENTS WITH DIFFUSE SYSTEMIC SCLEROSIS: RESULTS FROM THE PHASE IIB RISE-SSC STUDY (2019) (4)
Erosive arthritis autoantibodies in Systemic Sclerosis (2021) (3)
THU0330 EFFECTS OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED ILD (SSC-ILD) AND DIFFERING EXTENTS OF SKIN FIBROSIS: FURTHER ANALYSES OF THE SENSCIS TRIAL (2020) (3)
Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire (2021) (3)
OP0061 Update of Eular Recommendations for the Treatment of Systemic Sclerosis (2015) (3)
[Inducible nitric oxide synthase expression and nitric oxide production by monocytes in systemic sclerosis]. (2001) (3)
AB0621 From Vedoss To Established Systemic Sclerosis Diagnosis According To The New ACR/EULAR 2013 Classification Criteria: A French-Italian Capillaroscopic Survey (2016) (3)
A candidate gene study identifies a haplotype of CD2 as novel susceptibility factor for systemic sclerosis. (2016) (3)
Quality of life in SSc-ILD patients: Understanding the impact of the ILD and the needs of the SSc-ILD patients and their need for caregivers in France (2021) (3)
Phosphodiesterase 5 inhibitors in vascular systemic disorders. (2012) (3)
Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis (2021) (3)
OP0175 INTERNATIONAL MULTICENTRIC PROSPECTIVE STUDY ON PREGNANCY IN SYSTEMIC SCLEROSIS (IMPRESS-2) (2021) (3)
Sex-specific risk of anti-topoisomerase antibodies on mortality and disease severity in systemic sclerosis: 10-year analysis of the Leiden CCISS and EUSTAR cohorts (2022) (3)
Successful treatment with baricitinib of refractory arthritis in a patient with severe diffuse cutaneous systemic sclerosis-rheumatoid arthritis overlap syndrome. (2021) (3)
Spleen calcifications in connective tissue disorders. (2012) (3)
OP0055 Anti-RNA Polymerase III Antibodies in Patients with Systemic Sclerosis: A Eustar Multicenter Collaborative Study (2015) (3)
CP-150 Evaluation of infliximab (REMICADE) substitution by infliximab biosimilar (INFLECTRA): cost savings and therapeutic maintenance (2017) (3)
Erratum: Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations (Arthritis & Rheumatism (2790-2796)) (2011) (3)
POS0070 CONTINUED TREATMENT WITH NINTEDANIB IN PATIENTS WITH LIMITED CUTANEOUS SYSTEMIC SCLEROSIS (lcSSc) AND INTERSTITIAL LUNG DISEASE (ILD) (2022) (3)
Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit (2022) (3)
SAT0508 Ace-inhibitors in arterial hypertension in ssc patients display a risk factor for scleroderma renal crisis – a eustar analysis (2018) (3)
Clinical determinants of elevated systolic pulmonary artery pressure measured by transthoracic Doppler echocardiography in early systemic sclerosis. (2017) (3)
Influence of inflammatory and non-inflammatory rheumatic disorders on the clinical and biological profile of type-2 diabetes. (2021) (3)
Effect of nintedanib on progression of systemic sclerosis-associated interstitial lung disease (SSc-ILD) beyond 52 weeks: data from the SENSCIS trial (2020) (3)
Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON (2022) (3)
THU0014 A Regulatory Variant in CCR6 is Associated with Anti-Topoisomerase Positive Systemic Sclerosis Susceptibility (2013) (3)
OP0060 Impaired Quality of Life in Systemic Sclerosis and Patient Perception of the Disease: A Large International Survey (2015) (3)
Systemic sclerosis-related acute myocardial infarction: definition. (2014) (3)
Immunogenicity of Rituximab biosimilar GP2013 in chronic inflammatory rheumatic disorders in daily clinical practice. (2022) (3)
Disease course and outcome of progressive interstitial lung disease in systemic sclerosis (2019) (3)
Osteosarcoma presenting as a solitary focus of osteolysis in the calvarium. (2006) (3)
SAT0438 Clinical Characteristics of Systemic Sclerosis Patients with Digital Ulcer Disease Who Developed Gangrene: Data from the Duo Registry (2015) (3)
Association study of CRP gene in systemic sclerosis in European Caucasian population (2014) (3)
OP0142 Rituximab in systemic sclerosis : safety and efficacy data from the eustar network (2018) (2)
Rapidly Progressive Systemic Sclerosis–associated Interstitial Lung Disease After Intravesical Bacillus Calmette-Guérin Therapy for Early-stage Bladder Cancer (2021) (2)
OP0266 EFFICACY OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) AND INTERNAL ORGAN INVOLVEMENT: DATA FROM THE SENSCIS TRIAL (2021) (2)
FRI0265 Rituximab improves skin fibrosis and prevents worsening of lung function in patients with systemic sclerosis in the eustar cohort (2013) (2)
FRI0358 Contribution of the Adhesion Receptor DNAX Accessory Molecule-1 (DNAM-1) in the Development of Experimental Arthritis (2014) (2)
Prevalence of the different types of pulmonary hypertension in systemic sclerosis: Results from two large samples of European Caucasians And meta-analysis of five studies. (2010) (2)
Abnormal right ventricular diastolic function may not be the only early marker of myocardial involvement in systemic sclerosis. (2006) (2)
Low circulating endothelial progenitor cell levels and high VEGF serum levels are associated with the late nailfold capillaroscopic pattern in systemic sclerosis (2012) (2)
FRI0575 BIOMARKER ANALYSIS FROM THE RISE-SSC STUDY OF RIOCIGUAT IN EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC) (2020) (2)
Effect of Nintedanib on Progression of Systemic Sclerosis‐Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled Trial (2022) (2)
THU0061 Correlations Between Angiogenic Factors and Capillaroscopic Patterns in Systemic Sclerosis (2013) (2)
S.3.1 Watermelon stomach in SSc: a EUSTAR case–control study (2012) (2)
Effect of endothelin-1 receptor antagonists on skin fibrosis in scleroderma patients from the EUSTAR database (2016) (2)
POS0877 INTERSTITIAL LUNG DISEASE IN ANTI-U1RNP SYSTEMIC SCLEROSIS PATIENTS: A EUROPEAN SCLERODERMA TRIALS AND RESEARCH (EUSTAR) ANALYSIS (2022) (2)
Barrett’s oesophagus in systemic sclerosis (2007) (2)
SAT0541 More than Half of Diffuse Idiopathic Skeletal Hyperostosis Patients May Fulfill The ASAS Definition of A Positive MRI of The Spine: A Retrospective Analysis of 53 Cases (2016) (2)
Linking systemic angiogenic markers to synovial vascularization in rheumatoid arthritis (2018) (2)
Nailfold capillaroscopy in SSc: innocent bystander or promising biomarker for novel severe organ involvement/progression? (2022) (2)
OP0227 EFFECTS OF SUCCESSIVE SWITCHES TO DIFFERENT BIOSIMILARS INFLIXIMAB ON IMMUNOGENICITY IN CHRONIC INFLAMMATORY DISEASES IN DAILY CLINICAL PRACTICE (2019) (2)
Pulmonary arterial hypertension occurrence after liver transplant in systemic sclerosis: a report of 2 cases sustainably treated by sildenafil. (2010) (2)
POS0063 PROGRESSIVE INTERSTITIAL LUNG DISEASE IS FREQUENT ALSO IN LATE DISEASE STAGES IN SYSTEMIC SCLEROSIS PATIENTS FROM EUSTAR (2022) (2)
Evaluation of Patients With Rheumatoid Arthritis in Teleconsultation During the First Wave of the COVID-19 Pandemic (2022) (2)
Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort (2022) (2)
[Genetics and pathophysiology of systemic sclerosis]. (2011) (2)
THU0012 TGFβ receptor polymorphisms in systemic sclerosis related pulmonary arterial hypertension: Results from a multicenter eustar study of european caucasian patients (2013) (2)
THU0061 Vitamin D Insufficiency and Deficiency in Two European Cohorts of Patients with Inflammatory Rheumatic Disorders (2014) (2)
Safety and tolerability of nintedanib in patients with interstitial lung diseases in subgroups by sex: a post-hoc analysis of pooled data from four randomised controlled trials (2022) (2)
Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease (2020) (2)
Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from EUSTAR cohort. (2022) (2)
OP0068 ABATACEPT IN EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS— RESULTS OF A PHASE 2 INVESTIGATOR-INITIATED, MULTICENTER, DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL (2019) (2)
The power of the EUSTAR cohort: key findings to date and implications for management of systemic sclerosis patients (2020) (2)
Infections and systemic sclerosis: an emerging challenge (2020) (2)
Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort (2022) (2)
Treatment of systemic sclerosis associated ILD: Lessons from clinical trials. (2020) (2)
S.13.1 Safety and efficacy of rituximab in SSc: an analysis from the European Scleroderma Trial and Research Group (2012) (2)
JAMA Peer Reviewers in 2019. (2020) (1)
Pseudo-felty's syndrome. Report of a case with no symptoms for at least 15 years. (1996) (1)
Is sitaxsentan a good therapeutic option for pulmonary arterial hypertension associated with connective tissue disease? (2008) (1)
OP0131 Prevalence and Predictors of Small Intestinal Bacterial Overgrowth in Systemic Sclerosis (2013) (1)
SAT0116 Mortality Profile of Patients with Rheumatoid Arthritis in France and Its Change in 10 Years (2016) (1)
OP0095 Soluble cd163 as a potential biomarker in systemic sclerosis (2018) (1)
Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis (2022) (1)
SAT0467 The Five Prospective Observational Trials of the International Systemic Sclerosis FP7-Health Research Project Desscipher: A Interim Report (2015) (1)
Association of Fcγ receptor IIIA variant with a subset of anti-topoisomerase I-positive patients in systemic sclerosis: a descriptive pilot study (2012) (1)
OP0207 The outcomes of limited cutaneous systemic sclerosis patients: a eustar database study (2018) (1)
Representativeness of Systemic Sclerosis Patients in Interventional Randomized Trials: an analysis of the EUSTAR database. (2021) (1)
Basic (PS01–PS58) (2012) (1)
Prediction and Frequency of Progressive Lung Fibrosis in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the World’s Largest Database of Patients with Systemic Sclerosis (EUSTAR) (2019) (1)
Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Data from the SENSCIS-ON Trial (1)
Clinical and experimental scleroderma 2014. (2014) (1)
An update on recent randomized clinical trials in systemic sclerosis. (2021) (1)
Meeting abstracts from the 9th International Conference on cGMP: Generators, Effectors and Therapeutic Implications (2019) (1)
Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux disease (2022) (1)
SAT0474 Racial differences in ssc disease presentation: a european scleroderma trials and research group study (2018) (1)
SAT0513 Progressive skin fibrosis is associated with a decline in lung function and poorer survival in patients with diffuse cutaneous systemic sclerosis: a european scleroderma trials and research (EUSTAR) analysis (2018) (1)
OP0269 A COMBINED CLINICAL AND BIOMARKER ALGORITHM TO PREDICT FVC DECLINE IN SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE: RESULTS FROM AN INTERNATIONAL MULTICENTRE OBSERVATIONAL COHORT (2021) (1)
OP0157 EFFECT OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSc-ILD) AND RISK FACTORS FOR RAPID DECLINE IN FORCED VITAL CAPACITY: FURTHER ANALYSES OF THE SENSCIS TRIAL (2022) (1)
Sex influence on outcomes of patients with systemic sclerosis-associated interstitial lung disease: an EUSTAR database analysis. (2022) (1)
Corrigendum: The Nrf2-Antioxidant Response Element Signaling Pathway Controls Fibrosis and Autoimmunity in Scleroderma (2021) (1)
Lung Function Decline in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) by Time Since First Non-Raynaud Symptom: Subgroup Analysis of the SENSCIS Trial (2020) (1)
Use of platelet inhibitors for digital ulcers related to systemic sclerosis: EUSTAR study on derivation and validation of the DU-VASC model. (2022) (1)
OP0268 Prediction of Cardiac and Vascular Events in Systemic Sclerosis: Input from Endothelin-1 Type A Receptor Antibodies (2014) (1)
Systemic Sclerosis Associated Interstitial Lung Disease: A Conceptual Framework for Subclinical, Clinical, and Progressive Disease. (2022) (1)
Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region. (2022) (1)
POS0318 CLINICAL PHENOTYPE IN SCLERODERMA PATIENTS WITH ANTI-TOPOISOMERASE I POSITIVITY AND LIMITED CUTANEOUS FORM: DATA FROM THE EUSTAR DATABASE (2021) (1)
Impact and outcome of COVID-19 on SSc-ILD (2021) (1)
SAT0244 Active Skin Disease at Baseline Does Not Predict Progression of Skin Fibrosis at One Year Follow Up – A Eustar Analysis (2016) (1)
Prevalence and predictors of small intestinal bacterial overgrowth in systemic sclerosis patients with gastro-intestinal symptoms (2014) (1)
Predictive Value Of Non-Invasive Tests For The Diagnosis Of Scleroderma-Associated Pulmonary Hypertension: Pharos Registry (2011) (1)
THU0392 Systemic sclerosis and primary biliary cholangitis: an overlap syndrome? preliminary data from a multicentre eustar study (2018) (1)
AB0698 MID-Term Effects of Rituximab in Connective Tissue Disorders Related Interstitial Lung Disease (ILD) (2015) (1)
[Spondylarthropathies and anti-TNFalpha drugs]. (2005) (1)
Cohort enrichment strategies for progressive interstitial lung disease in systemic sclerosis from EUSTAR. (2022) (1)
Increased antibody response after SARS-CoV-2 mRNA-based vaccination in rituximab-treated patients with previous COVID-19 infection (2022) (1)
SP0230 The Co-Occurrence of Other Autoimmune Diseases within Patients with Systemic Sclerosis (2015) (1)
Comprar Scleroderma. From Pathogenesis To Comprehensive Management 2nd Ed. | John Varga | 9783319314051 | Springer (2016) (1)
SAT0204 The Eular Systemic Sclerosis Impact of Disease (ScleroID) Score – A New Patient-Reported Outcome Measure for Patients with Systemic Sclerosis under Development (2016) (1)
Length Double-blind , Randomized , 8-week Placebo-controlled followed by a 16-week open label extension study , with the LPA 1 receptor antagonist SAR 100842 for Patients With Diffuse Cutaneous Systemic Sclerosis (2018) (1)
Safety and effi cacy of subcutaneous tocilizumab in adults with systemic sclerosis ( faSScinate ) : a phase 2 , randomised , controlled trial (2016) (1)
Driving Role of Interleukin‐2–Related Regulatory CD4+ T Cell Deficiency in the Development of Lung Fibrosis and Vascular Remodeling in a Mouse Model of Systemic Sclerosis (2022) (1)
OP0031 Risk Factors for Malignancies Synchronous To The Onset of Systemic Sclerosis in Patients Positive for Anti- RNA Polymerase III Antibodies: A Eustar Multicentre Study (2016) (1)
Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models (2022) (1)
Persistent inflammation in systemic sclerosis is strongly associated with mortality: a EUSTAR database analysis (2022) (1)
[Simultaneous onset of rheumatoid polyarthritis and type 1 diabetes]. (2000) (1)
[Watermelon stomach in systemic sclerosis]. (2010) (1)
THU0425 18f-fluorodeoxyglucose positron emission tomography/computed tomography and lung involvement in systemic sclerosis (2018) (1)
THU0351 MUSCLE INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS AND ANTI-PM/SCL+ ANTIBODIES IS ASSOCIATED WITH CARDIAC AND PULMONARY INVOLVEMENT. ANALYSIS OF THE MULTICENTRE EUSTAR COHORT. (2020) (0)
FRI0471 Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the spar model (2018) (0)
AB1236 CLINICAL CHARACTERISTICS OF JUVENILE ONSET SYSTEMIC SCLEROSIS PATIENTS FROM THE JUVENILE SCLERODERMA INCEPTION COHORT COMPARED TO ADULT AGE JUVENILE-ONSET PATIENTS FROM EUSTAR. ARE THESE DIFFERENCES SUGGESTING RISK FOR MORTALITY? (2022) (0)
[Ossification of the common posterior longitudinal ligament of the spine and spinal cord compression in a patient from Senegal]. (2005) (0)
OP0227 Critical Role of the Adhesion Receptor DNAX Accessory Molecule-1 (DNAM-1) in the Development of Inflammation-Driven Dermal Fibrosis in Mouse Model of Systemic Sclerosis (2013) (0)
Challenging diagnosis of renal failure associated with severe neurological symptoms in a patient with mixed connective tissue disease (2022) (0)
FRI0268 Safety and Efficacy of Subcutaneous Tocilizumab in Early Systemic Sclerosis: Results from The Open-Label Period of The Fasscinate Trial (2016) (0)
SAT0244 Association Between Spondyloarthritis and Takayasu Arteritis: a Study of 14 Cases (2015) (0)
FRI0461 Immunosuppressive “Routine” Treatment of of SSC Patients with Interstitial Lung Disease – Results of the FP7 Desscipher Project of the Eustar Group (2015) (0)
SAT0481 Setting the standard for longitudinal follow-up of systemic sclerosis; a eustar delphi-based expert consensus (2018) (0)
Assessment of hand involvement in systemic sclerosis by ultrasonography. Reply. (2013) (0)
FRI0270 Patient Perception of Disease Burden in Diffuse Cutaneous Systemic Sclerosis (DcSSc) (2016) (0)
Characteristics of patients with difficult-to-treat rheumatoid arthritis in a French single-centre hospital. (2023) (0)
POS0893 FACTORS TO CONSIDER FOR MEASURING THE EFFECT OF LUNG FUNCTION ON PATIENT REPORTED OUTCOMES IN SYSTEMIC SCLEROSIS PATIENTS: ANALYSIS OF THE EUSTAR DATABASE. (2022) (0)
Antibodies against periodontal pathogens are not associated with joint swelling or autoimmunity associated with RA in a cohort of healthy individuals at increased risk of rheumatoid arthritis (2015) (0)
POS0321 USE OF HYDROXYCHLOROQUINE AND SYSTEMIC SCLEROSIS: RESULTS FROM A PROSPECTIVE OBSERVATIONAL STUDY ON THE EUSTAR COHORT (2021) (0)
POS0877 THE EFFECT OF PLATELET INHIBITORS ON DIGITAL ULCERS IN SYSTEMIC SCLEROSIS - A DERIVATION AND VALIDATION EUSTAR STUDY (2021) (0)
Drs. Allanore and Vacca reply (2010) (0)
IRF8 Gene Contributes to Disease Susceptibility and Interacts withNF-KB By Modulating Interferon Signature in Patients with SystemicSclerosis (2014) (0)
AB0431 EXPLORING THE UTILITY OF THE AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CRISS IN PATIENTS WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (2021) (0)
SAT0366 Smoking behaviour and the progression of organ manifestations in systemic sclerosis: a longitudinal european scleroderma trials and research group study (2017) (0)
SAT0511 Practical suggestions on intravenous iloprost in raynaud’s phenomenon and digital ulcer secondary to systemic sclerosis: systematic literature review and expert consensus (2018) (0)
Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression (2023) (0)
FRI0052 INFLUENCE OF RHEUMATOID ARTHRITIS ON THE CLINICAL AND BIOLOGICAL PROFILE OF TYPE-2 DIABETES MELLITUS (2020) (0)
THU0068 Prevalence of dyslipidaemia in an early arthritis rheumatoid cohort (ESPOIR cohort). Lack of improvement after 4 years of follow-up (2013) (0)
POS1230 INCREASED ANTIBODY RESPONSE AFTER SARS-CoV-2 mRNA-BASED VACCINATION IN RITUXIMAB-TREATED PATIENTS WITH PREVIOUS COVID-19 INFECTION (2022) (0)
SP0035 Raynaud’s phenomenon and systemic sclerosis: An update (2013) (0)
AB0206 Pan-Ppar Agonist IVA337 is Effective in Prevention and Treatment of Experimental Skin Fibrosis (2015) (0)
OP0144 Intravenous versus oral cyclophosphamide (CYC) for the treatment of interstitial lung involvement (ILD) and skin involvement in systemic sclerosis (SSC): safety and efficacy evaluation in a large multi-centre scleroderma cohort (2018) (0)
Joint and Tendon Involvement Predict Severe Disease Progression inSystemic Sclerosis: A Prospective Study (2014) (0)
Author Correction: Raynaud phenomenon and digital ulcers in systemic sclerosis (2021) (0)
Enhanced expression of ephrins and thrombospondins in the dermis of patients with early diffuse systemic sclerosis (2010) (0)
OP0038 IMPROVING RISK-STRATIFICATION OF RHEUMATOID ARTHRITIS PATIENTS FOR INTERSTITIAL LUNG DISEASE (2020) (0)
FRI0438 Treatment with Abatacept Prevents Experimental Dermal FIBrosis and Induces Regression of Established Fibrosis in a Preclinical Model of Systemic Sclerosis (2015) (0)
SAT0380 Classification, categorisation and essential items for digital ulcer (DU) evaluation in systemic sclerosis (SSC): a desscipher/eustar survey (2017) (0)
THU0415 Anti-pm/scl antibody clinical associations in patients with systemic sclerosis. analysis of the multicenter eustar cohort (2018) (0)
OP0030 Associated Factors with Mortality and Derivation of A Simple 5-Factors To Predict Mortality in Ssc-Patients in The Eustar Cohort (2016) (0)
FRI0404 Cardiac blocks in systemic sclerosis: prevalence and associated features in the eustar cohort (2013) (0)
Abstract 3154: Cardiovascular Morbidity And Mortality In Rheumatoid Arthritis: A Systematic Review And Meta-analysis Of Cohort Studies (2008) (0)
POS0205 SAFETY AND TOLERABILITY OF NINTEDANIB IN PATIENTS WITH AUTOIMMUNE DISEASE-RELATED INTERSTITIAL LUNG DISEASES (ILDs) IN SUBGROUPS BY SEX AND AGE (2022) (0)
POS0900 SYSTEMIC PHARMACOLOGICAL TREATMENT OF DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: A SYSTEMATIC LITERATURE REVIEW (2022) (0)
Digital ulcers in systemic sclerosis (2020) (0)
OP0230 Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: a 12-year longitudinal multi-centre study (2018) (0)
Cohort and Possible Recommendations for Screening Systemic Sclerosis : Analysis of the EULAR Scleroderma Trials and Research Malignancies in Patients with Anti-RNA Polymerase III Antibodies and (2017) (0)
Reply (2019) (0)
FRI0242 Watermelon stomach in systemic sclerosis: A EUSTAR case-control study (2013) (0)
Assessment of vitamin D deficiency and insufficiency in 2 independent cohorts of patients with systemic sclerosis (2008) (0)
SAT0273 PREDICTIVE VALUE OF THE REVISED EUROPEAN SCLERODERMA TRIALS AND RESEARCH GROUP ACTIVITY INDEX (EUSTAR-AI) (2019) (0)
OP0139 Targeting IL-6 by Both Passive or Active Immunization Strategies Prevents Inflammation-Driven Skin Fibrosis (2014) (0)
New Insights into the Pathogenesis of Giant Cell Arteritis through a Genome-Wide Association Study (2016) (0)
Systemic Sclerosis : Results from 2 Large European Caucasian Cohorts Autoimmune Risk Loci in CD 58 and ITGAM , ITGAX , Association Study of YANNICK ALLANORE (2011) (0)
THU0400 Incidence and risk factors for gangrene in patients with systemic sclerosis from the eustar cohort (2018) (0)
Impact of Forced Vital Capacity Decline on Hospitalization Events in Systemic Sclerosis-Associated Interstitial Lung Disease: A Joint Model Analysis Using Data from the SENSCIS® Trial (0)
OP0304 Estrogens Inhibit The Profibrotic Effects of Tgf-Beta and Protect from The Development of Experimental Dermal Fibrosis (2016) (0)
SAT0316 Key Role of Cardiac Biomarkers in the Assessment of Systemic Sclerosis: Contribution of High Sensitivity Cardiac Troponin (2014) (0)
FRI0446 Severe Heart Disease in Systemic Sclerosis: Prevalence, Risk Factors and Current Treatment. A Eustar-Desscipher Study (2015) (0)
POS0378 CCN1: AN ANGIOGENIC ACTOR IMPLICATED IN THE STRUCTURAL DAMAGES OF RHEUMATOID ARTHRITIS (2021) (0)
FRI0269 Diffuse Cutaneous Systemic Sclerosis (dcSSc) Referral and Diagnosis: Results of A Survey of Healthcare Providers (2016) (0)
Comparison with Rheumatoid Arthritis and Influence of Glucocorticoid Trabecular Bone Score in Female Patients with Systemic Sclerosis: (2014) (0)
THU0409 Management of systemic sclerosis (SSC) related digital ulcers (DU) in expert tertiary centres: results from the analysis of the multicentre observational real-life desscipher/eustar study (2018) (0)
FRI0259 Increased risk of osteoporosis and fracture in women with systemic sclerosis: A comparative study to rheumatoid arthritis and healthy controls (2013) (0)
POS0600 IMMUNOGENICITY OF RITUXIMAB BIOSIMILAR GP2013: A RARE EVENT, BUT NOT WITHOUT CONSEQUENCES ... (2021) (0)
OP0170 DECLINE IN FORCED VITAL CAPACITY (FVC) IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) WITH AND WITHOUT DYSPNOEA: DATA FROM THE SENSCIS TRIAL (2021) (0)
Effect of a Diet Program on Lipid and Lipoproteins, Body Weight, Nutrient Intakes, and Quality of Life in Patients with Systemic Lupus Erythematosus (2008) (0)
AB0787 The eular systemic sclerosis impact of disease (SCLEROID) score – a new patient-reported outcome measure for patients with systemic sclerosis (2018) (0)
A new method to estimate the long-term effect of immunosuppressants and vasodilator therapies on lung function outcomes in systemic sclerosis patients (2020) (0)
Anti periplakin antibodies in connective tissue-associated lung fibrosis (2013) (0)
The functional MUC5B rs35705950 promoter polymorphism is associated with IPF but not with systemic sclerosis related interstitial lung disease (2012) (0)
Decline in Forced Vital Capacity (FVC) in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) with and without Cough: Data from the SENSCIS Trial (0)
OP0339 Identification of a transcriptomic signature correlated with modified rodnan skin score (MRSS) in patients with diffuse cutaneous systemic sclerosis (2017) (0)
THU0113 Linking systemic angiogenic markers to synovial vascularisation in rheumatoid arthritis (2018) (0)
SAT0227 The Efficacy of Vasoactive and Vasodilating Drugs on Digital Ulcers Healing in Systemic Sclerosis: Data from The Desscipher Observational Study of Eustar Group (2016) (0)
POS0066 THE PHENOTYPE OF MIXED CONNECTIVE TISSUE DISEASE PATIENTS HAVING ASSOCIATED INTERSTITIAL LUNG DISEASE (2022) (0)
04. Outcomes, Quality of Life, Psychological & Social (2018) (0)
Abstract 1639: Trends in Cardiovascular Mortality in Patients With Rheumatoid Arthritis Over 50 years: A Systematic Review and Meta-analysis of Cohort Studies (2009) (0)
USE OF IMMUNOSUPPRESSANTS IN SSC PATIENTS WITH INTERSTITIAL LUNG DISEASE - RESULTS OF THE DESSCIPHER PROJECT OF THE EUSTAR GROUP (2014) (0)
SP0071 WIN: SYSTEMIC SCLEROSIS – INNOVATIVE TREATMENT TARGETS OR “LOST IN TRANSLATION”? (2019) (0)
AB0242 Evidence for caveolin-1 (CAV1) as a new susceptibility gene regulating tissue fibrosis in systemic sclerosis (2013) (0)
HLA-G a putative susceptibility gene in scleroderma, but only in women (2012) (0)
AB0627 Rise-ssc: a double-blind, randomised study evaluating the efficacy and safety of riociguat for the treatment of patients with diffuse cutaneous systemic sclerosis (2017) (0)
A echocardiography in systemic sclerosis magnetic resonance imaging and tissue Doppler myocardial perfusion and contractility using cardiac Evaluation of the effect of nifedipine upon (2005) (0)
Tendons, Joints, and Bone (2012) (0)
FRI0248 Predictors of Disability in Systemic Sclerosis: A Study from The Desscipher Project (2016) (0)
FRI0330 MALIGNANCIES IN SYSTEMIC SCLEROSIS PATIENTSWITH ANTI-PM/SCL ANTIBODIES: AN EUSTAR CASE- CONTROL STUDY (2019) (0)
S.12.1 Is H1N1 influenza vaccine safe and effective in patients with SSc (2012) (0)
POS0538 PREDICTING VALUE OF CIRCULATING SEMAPHORIN 4A FOR RHEUMATOID ARTHRITIS PROGRESSION (2022) (0)
Progression of Skin Fibrosis Is Associated with Decline in Lung Function in Patients with Diffuse Cutaneous Systemic Sclerosis: A European Scleroderma Trials and Research (EUSTAR) Analysis (2019) (0)
OP0251 THE EULAR SYSTEMIC SCLEROSIS IMPACT OF DISEASE (SCLEROID) SCORE – A NEW PATIENT-REPORTED OUTCOME MEASURE FOR PATIENTS WITH SYSTEMIC SCLEROSIS (2020) (0)
Editor's acknowledgement (2005) (0)
The Effect of Body Fat Distribution on Systemic Sclerosis (2022) (0)
Session 4: An Integrated Approach to Gastro-intestinal Involvement (2014) (0)
Evidence for Caveolin-1 (CAV1) as a new susceptibility gene regulating tissue fibrosis in systemic sclerosis (2012) (0)
SAT0038 SEMAPHORINS: FROM ANGIOGENESIS TO INFLAMMATION IN RHEUMATOID ARTHRITIS (2019) (0)
Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid decline in forced vital capacity: further analyses of the SENSCIS trial* (2023) (0)
Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Interim Analysis of SENSCIS-ON (2021) (0)
AB0642 Efficacy of anakinra in gouty arthritis in real life population: a report of 36 cases. (2013) (0)
OP0291 ACTIVATION OF THE DEACETYLASE SIRTUIN-1 COUNTERACTS THE ACTIVATED AND PROANGIOGENIC PROFILE OF ENDOTHELIAL CELLS IN RHEUMATOID ARTHRITIS AND ALLEVIATES EXPERIMENTAL ARTHRITIS (2019) (0)
OP0160 Evaluation of Non-Invasive Tests as an Early Diagnostic Screen for Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis (2013) (0)
Risk stratification using anti-citrullinated peptide antibodies (ACPA) in polyarticular subtypes of juvenile idiopathic arthritis in adulthood. (2022) (0)
A Diffuse Scleroderma Patient Who Presents with Shortness of Breath and Enlarged Cardiac Silhouette (2011) (0)
POS0140 PREDICTING OUTCOMES IN SYSTEMIC SCLEROSIS: STRATIFICATION BY AUTO-ANTIBODIES OUTPERFORMS CUTANEOUS SUBSETTING IN THE EUSTAR COHORT (2022) (0)
Iconography : Incomplete thymic involution in systemic sclerosis and rheumatoid arthritis (2012) (0)
FRI0484 Nailfold Videocapillaroscopy Patterns Associated with Calcinosis and Acro-Osteolysis in Systemic Sclerosis (2014) (0)
OP0060-HPR Cross-Cultural Validation of The Systemic Sclerosis Quality of Life Questionnaire in Six European Countries: A Tool Validation Study (2016) (0)
THU0106 Identification of Markers Associated with The Occurrence of Interstitial Lung Disease in Rheumatoid Arthritis Patients (2016) (0)
OP0282 New systemic sclerosis risk loci identified through a meta-gwas strategy (2018) (0)
The Arachidonate 5-Lipoxygenase Activating Protein (ALOX5AP) Polymorphism Is Associated with Risk of Scleroderma-Related Interstitial Lung Disease (2012) (0)
F212 COMPARISON OF FREQUENCY, TYPE AND IMPACT OF PAIN AND PAIN MANAGEMENT IN RHEUMATOID ARTHRITIS AND SYSTEMIC SCLEROSIS (2011) (0)
Basic and translational research (2011) (0)
Dr. Pène, et al reply (2016) (0)
Modelling Short-Term FVC Changes from SENSCIS to Long-Term FVC Course in SSc-ILD Demonstrates Clinically Meaningful Reduction of FVC Decline and Survival Benefits (0)
[Psoriatic arthritis]. (2002) (0)
THU0006 Trans-ethnic meta-analysis of genome-wide association studies identifies GSDMA and PRDM1 as susceptibility genes to systemic sclerosis (2017) (0)
FRI0390 European multicentre study validates elf test as biomarker of fibrosis in systemic sclerosis (2017) (0)
POS0861 EFFECTIVENESS AND SAFETY OF TOCILIZUMAB IN PATIENTS WITH SYSTEMIC SCLEROSIS: A PROPENSITY SCORE CONTROL MATCHED OBSERVATIONAL STUDY OF THE EUSTAR COHORT (2021) (0)
Digital Ulcers, Vasculopathy and Internal Organ Involvement (2018) (0)
The Phenotype of Mixed Connective Tissue Disease Patients Having Associated Interstitial Lung Disease (2022) (0)
OP0182 Angiogenic biomarkers predict the occurrence of digital ulcers in systemic sclerosis (2013) (0)
Systemic sclerosis and primary biliary cholangitis: Longitudinal data to determine the outcomes (2023) (0)
POS0855 PATIENT PREFERENCES, TRADE-OFFS AND ACCEPTABLE RISKS IN THE TREATMENT OF SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: A STEP TOWARDS SHARED DECISION-MAKING (2021) (0)
POS0640 REAL-WORLD EFFECTIVENESS AND SAFETY OF GP2015 IN PATIENTS WITH RHEUMATIC DISEASES: FINAL RESULTS OF THE COMPACT STUDY (2022) (0)
FRI0263 Nodular Regenerative Hyperplasia of The Liver – A Rare Vascular Complication of SSC (2016) (0)
Development of a composite index for clinical trials in early diffuse cutaneous systemic sclerosis - the combined response index in systemic sclerosis (2014) (0)
POS0316 MODELLING SHORT-TERM FVC CHANGES FROM SENSCIS TO LONG-TERM FVC COURSE IN SSc-ILD DEMONSTRATES CLINICALLY MEANINGFUL REDUCTION OF FVC DECLINE AND SURVIVAL BENEFITS (2021) (0)
PRS3 Joint Modelling of Forced Vital Capacity Decline and Time to Hospitalization Outcomes in Systemic Sclerosis-Associated Interstitial Lung Disease (2021) (0)
Survival and prognosis factors in systemic sclerosis: Data of a French multicenter cohort of incident patients, systematic review and meta-analysis of the literature (2017) (0)
Severe immune thrombocytopenia in two patients with systemic sclerosis. (2023) (0)
SAT0439 Prediction of Improvement in Skin Fibrosis in Diffuse Cutaneous Systemic Sclerosis – a Eustar Analysis (2015) (0)
SAT0328 OUTCOME OF INTERSTITIAL LUNG DISEASE (ILD) IN ANTI-PM/SCL PATIENTS WITH SYSTEMIC SCLEROSIS: RESULTS FROM AN EUSTAR CASE-CONTROL STUDY. (2020) (0)
POS0375 EVALUATION OF PATIENTS WITH RHEUMATOID ARTHRITIS IN TELECONSULTATION DURING THE FIRST WAVE OF THE COVID-19 PANDEMIC (2022) (0)
The role of antifibrotic therapies in the treatment of systemic sclerosis–associated interstitial lung disease (2022) (0)
POS0888 NON-SURGICAL LOCAL TREATMENTS FOR DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: A SYSTEMATIC LITERATURE REVIEW (2022) (0)
FRI0285 Sensitivity To Change of Nailfold Videocapillaroscopy and Relationship with Disease Progression (2016) (0)
SAT0254 VASODILATOR THERAPY IN THE LONG TERM PREVENTION OF MYOCARDIAL MANIFESTATIONS IN SYSTEMIC SCLEROSIS (SSC): RESULTS FROM DESSCIPHER INCEPTION COHORT STUDY (2019) (0)
Abstracts from the 4th Systemic Sclerosis World Congress February 18–20, 2016 - Lisbon, Portugal (2016) (0)
FRI0370 Joint and tendon involvement predict severe disease progression in systemic sclerosis: a eustar prospective study (2013) (0)
AB0269 UTILITY OF DAS28-γGT IN THE ASSESSMENT OF DISEASE ACTIVITY AND CARDIOVASCULAR RISK IN RHEUMATOID ARTHRITIS (2022) (0)
AB0657 Severity and impact of gastrointestinal symptoms in patients with SSc-ILD treated with nintedanib: data from SENSCIS-ON (2022) (0)
OP0089 Abatacept is effective in experimental digestive and lung tissue fibrosis (2018) (0)
POS0898 SURGICAL MANAGEMENT OF DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: A SYSTEMATIC LITERATURE REVIEW. (2022) (0)
Targeting CD226/DNAX accessory molecule-1 (DNAM-1) in collagen-induced arthritis mouse models (2015) (0)
FRI0491 Incidence and Predictors of Cutaneous Manifestations During the Early Course of Systemic Sclerosis – A 10 Year Longitudinal Study from the Eustar Database (2015) (0)
AB0665 SWITCHING INTRAVENOUS ABATACEPT AND TOCILIZUMAB TO SUBCUTANEOUS INJECTIONS DURING THE COVID-19 PANDEMIC: A FRENCH EXPERIENCE (2021) (0)
A Cross-sectional Study Manifestations in a Large Series of French Patients with Systemic Sclerosis : Anti-RNA Polymerase III Antibody Prevalence and Associated Clinical (2009) (0)
Ochronosis of the spine mimicking ankylosing spondylitis successfully treated with IL-1 receptor antagonist anakinra. (2020) (0)
FRI0447 Worldwide expert agreement on updated eular/eustar recommendations for the treatment of systemic sclerosis (2018) (0)
OP0072 Medium-Term Safety of Tnf-Alpha Inhibitors in Rheumatoid Arthritis: A Meta-Analysis of Randomized Controlled Trials (2014) (0)
POS1228 THE ROLE OF CHEST CT IN UNDERSTANDING INTERSTITIAL LUNG DISEASE (ILD): SYSTEMIC SCLEROSIS (SSc). VERSUS COVID-19 (2021) (0)
O27 Subcutaneous Tocilizumab in Adults with Systemic Sclerosis: 24 and 48 Week Safety and Efficacy Data from the Fasscinate Trial (2016) (0)
AB0669 The eular systemic sclerosis impact of disease (SCLEROID) score – a new patient-reported outcome measure for patients with systemic sclerosis – preliminary results from the ongoing validation study (2017) (0)
Title: European multicentre study validates ELF test as biomarker of fibrosis in systemic sclerosis  (2018) (0)
Safety and eﬀicacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial (2022) (0)
Feasibility and Efficacy of Cohort Enrichment for Progressive Lung Fibrosis in Systemic Sclerosis - a EUSTAR Database Analysis (2019) (0)
Identification of a New Set of Activity Criteria for Systemic Sclerosis. Preliminary Report (2015) (0)
POS0383 CLINICAL CHARACTERISTICS AND PROGNOSIS OF PATIENTS WITH SYSTEMIC SCLEROSIS SINE SCLERODERMA: DATA FROM THE INTERNATIONAL EUSTAR DATABASE. (2022) (0)
FRI0458 Association Between Number and Size of Cutaneous Telangiectasia with Microcirculation Abnormalities Detected by Naifold Videocapillaroscopy in Systemic Sclerosis (2015) (0)
THU0190 METHOTREXATE THERAPY IS NOT ASSOCIATED WITH AN INCREASED RISK OF LIVER FIBROSIS ASSESSED BY THE FIBROSIS-4 INDEX (2020) (0)
POS0858 NAILFOLD VIDEOCAPILLAROSCOPY FINDINGS AND ASSOCIATIONS WITH ORGAN INVOLVEMENT IN MIXED CONNECTIVE TISSUE DISEASE (2022) (0)
OP0290 Ox40l Blockade Protects against Skin and Lung Inflammation-Driven Fibrosis (2016) (0)
OP0273 CHARACTERISTICS OF PATIENTS WITH DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS IN FRANCE (2022) (0)
POS0317 THE PERFORMANCE OF DIFFUSING CAPACITY FOR MONOXIDE CARBON (DLCO) AND FORCED VITAL CAPACITY (FVC) IN PREDICTING THE ONSET OF SYSTEMIC SCLEROSIS (SSc)-INTERSTITIAL LUNG DISEASE (ILD) IN THE EUROPEAN SCLERODERMA TRIALS AND RESEARCH (EUSTAR) DATABASE (2021) (0)
FRI0698 Survey of 1,318 patients on their knowledge of the pulmonary manifestations of rheumatoid arthritis and their needs in terms of information and follow-up (2018) (0)
Endothelial Progenitor Cells: A Vascular Perspective for Inflammatory Rheumatic Disorders (2007) (0)
AB0774 Impact of standardised education program on the accuracy of modified rodnan skin scoring in patients with systemic sclerosis (2018) (0)
Reply (2013) (0)
sclerosis Doppler echocardiography in systemic cardiac magnetic resonance imaging and tissue myocardial perfusion and contractility using Evaluation of the effect of nifedipine upon and (2005) (0)
POS0873 PERSISTENT INFLAMMATION IN SYSTEMIC SCLEROSIS IS STRONGLY ASSOCIATED WITH SEVERE DISEASE AND MORTALITY: AN ANALYSIS FROM THE EUSTAR DATABASE (2022) (0)
FRI0456 Predictors for disease worsening defined by organ failure in diffuse systemic sclerosis: a european scleroderma trials and research (EUSTAR) analysis (2018) (0)
SAT0196 Impress 2 (International Multicentric Prospective Study on Pregnancy in Systemic Sclerosis). Prospective, Case-Control Study of Pregnancy in Systemic Sclerosis (2016) (0)
FRI0146 Levels of ultrasensitive troponin and nt-probnp in rheumatoid arthritis (2013) (0)
FRI0325 IDENTIFYING SYSTEMIC SCLEROSIS PATIENTS AT RISK OF PROGRESSIVE LUNG FIBROSIS – A EUSTAR DATABASE ANALYSIS (2019) (0)
systemic sclerosis . “ Pearls and pitfalls ” Algorithm of heart disease in scleroderma (2017) (0)
Association polyarthrite rhumatoïde et cirrhose biliaire primitive Association between rheumatoid arthritis and primary biliary cirrhosis (2007) (0)
Gastroesophageal reflux and serum biomarkers in systemic sclerosis‐related interstitial lung disease. Reply (2019) (0)
[Treatment of systemic scleroderma: update]. (2006) (0)
FRI0541 A Cross-Sectional, International Survey on Non-Invasive Techniques To Assess The Microcirculation in Patients with Raynaud's Phenomenon (Sunshine Survey) (2016) (0)
ALPN-101 (Acazicolcept) a Dual ICOS/CD28 Antagonist, Demonstrates Efficacy in Systemic Sclerosis Preclinical Mouse Models (2021) (0)
Diagnosis of Giant Cell Arteritis : Analysis of 77 Subjects Limited Value of Temporal Artery Ultrasonography Examinations for GUILLEVIN (2010) (0)
FRI0393 Predictive value of history of digital ulcers in a eustar cohort of patients with systemic sclerosis (2013) (0)
Consensus on the assessment of systemic sclerosis–associated primary heart involvement: World Scleroderma Foundation/Heart Failure Association guidance on screening, diagnosis, and follow-up assessment (2023) (0)
SAT0198 The Desscipher Project in Systemic Sclerosis (SSC): Observational Data on Digital Ulcers (DU) Prevention from The Eustar Group (2016) (0)
0232 : Small, medium but not large arteries are involved in digital ulcers associated with systemic sclerosis (2015) (0)
PMS52 Quality of Life in Ssc-ILD Patients: Understanding the IMPACT of the ILD and the NEEDS of the Ssc-ILD Patients and Their Caregivers in France (2020) (0)
Sustained complete B cell depletion is associated with rituximab efficacy in connective tissue disorders-associated interstitial lung disease (2023) (0)
OP0081 PAN-PPAR agonist IVA337 is effective in the prevention of experimental lung fibrosis and pulmonary hypertension (2017) (0)
Systemic sclerosis, a comprehensive approach (2020) (0)
Stem Cells: Hope for Systemic Sclerosis Patients? (2019) (0)
Thanks to reviewers in 2010 (2010) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Yannick Allanore?

Yannick Allanore is affiliated with the following schools:

Yannick Allanore's Academic­Influence.com Rankings

Yannick Allanore's Degrees

Why Is Yannick Allanore Influential?

Yannick Allanore's Published Works

Published Works

What Schools Are Affiliated With Yannick Allanore?

Yannick Allanore's AcademicInfluence.com Rankings